Influence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT).

Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm (2015) 1.70

Myocardial structural associations with local electrograms: a study of postinfarct ventricular tachycardia pathophysiology and magnetic resonance-based noninvasive mapping. Circ Arrhythm Electrophysiol (2012) 0.98

Prophylactic catheter ablation of ventricular tachycardia before cardioverter-defibrillator implantation in patients with non-ischemic cardiomyopathy: Clinical outcomes after a single endocardial ablation. J Arrhythm (2015) 0.82

Non-invasive programmed stimulation to identify high-risk patients with implanted cardioverter defibrillator (the NIPS-ICD study): study protocol for a randomized controlled trial. Trials (2016) 0.75

A Questionable Indication For ICD Extraction After Successful VT Ablation. J Atr Fibrillation (2015) 0.75

Predictors of success in ablation of scar-related ventricular tachycardia. Clin Med Insights Cardiol (2013) 0.75

Ventricular tachycardia ablation: what have we learned from SMASH-VT. J Cardiovasc Electrophysiol (2010) 0.75

Contemporary Mapping Techniques of Complex Cardiac Arrhythmias - Identifying and Modifying the Arrhythmogenic Substrate. Arrhythm Electrophysiol Rev (2015) 0.75

Imaging-Based Simulations for Predicting Sudden Death and Guiding Ventricular Tachycardia Ablation. Circ Arrhythm Electrophysiol (2017) 0.75

Prophylactic mechanical hemodynamic support for catheter ablation of VT: locking the barn door before the horse has bolted. J Interv Card Electrophysiol (2016) 0.75

Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA (2010) 8.53

2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm (2012) 8.03

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace (2012) 5.84

Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol (2013) 5.67

Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med (2007) 5.05

Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation (2011) 4.95

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68

Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol (2013) 4.07

A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol (2008) 3.58

Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol (2009) 3.09

Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis (2006) 3.04

Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. Radiology (2007) 2.93

Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol (2007) 2.90

EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm (2009) 2.89

The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol (2012) 2.50

Use of the electrocardiogram in acute myocardial infarction. N Engl J Med (2003) 2.40

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38

Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. JACC Cardiovasc Imaging (2009) 2.33

The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg (2008) 2.29

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14

2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08

Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence? J Virol (2002) 1.93

Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm (2006) 1.87

EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace (2009) 1.83

Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. Heart Rhythm (2009) 1.82

Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J Immunol (2004) 1.81

Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm (2011) 1.80

Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med (2004) 1.78

Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol (2009) 1.77

QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter-defibrillators. J Am Coll Cardiol (2005) 1.76

Non-inducibility post-pulmonary vein isolation achieving exit block predicts freedom from atrial fibrillation. Eur Heart J (2005) 1.74

Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm (2010) 1.74

Effects of ventricular premature stimulus coupling interval on blood pressure and heart rate turbulence. Circulation (2002) 1.73

Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging (2004) 1.73

Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol (2006) 1.68

Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med (2008) 1.68

Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail (2014) 1.60

Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation (2002) 1.58

Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure. Circ Arrhythm Electrophysiol (2011) 1.56

T-vector direction differentiates postpacing from ischemic T-wave inversion in precordial leads. Circulation (2005) 1.54

Timing of delayed perforation with the St. Jude Riata lead: a single-center experience and a review of the literature. Heart Rhythm (2008) 1.53

Mode of induction of ventricular tachycardia and prognosis in patients with coronary disease: the Multicenter UnSustained Tachycardia Trial (MUSTT). J Cardiovasc Electrophysiol (2009) 1.51

Paroxysmal atrioventricular block. Heart Rhythm (2009) 1.48

Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci (2004) 1.48

Echocardiographic measures of acute haemodynamic response after cardiac resynchronization therapy predict long-term clinical outcome. Eur Heart J (2007) 1.48

Use of electrogram characteristics during sinus rhythm to delineate the endocardial scar in a porcine model of healed myocardial infarction. J Cardiovasc Electrophysiol (2003) 1.47

In-hospital management of atrial fibrillation: the CHADS₂ score predicts increased cost. Can J Cardiol (2011) 1.46

Characterization of the infarct substrate and ventricular tachycardia circuits with noncontact unipolar mapping in a porcine model of myocardial infarction. Heart Rhythm (2006) 1.45

Effectiveness of a real-time clinical decision support system for computerized physician order entry of plasma orders. Transfusion (2013) 1.45

Security and privacy qualities of medical devices: an analysis of FDA postmarket surveillance. PLoS One (2012) 1.40

Group beating related T-wave alternans in a patient with atrio-ventricular nodal reentrant tachycardia. Europace (2011) 1.40

Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2010) 1.40

Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem (2006) 1.39

The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm (2013) 1.39

Inducibility of atrial fibrillation with a synchronized external low energy shock post-pulmonary vein isolation predicts recurrent atrial fibrillation. J Cardiovasc Electrophysiol (2008) 1.38

Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation (2004) 1.37

Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J Virol (2008) 1.36

Impact of sleep on arrhythmogenesis. Circ Arrhythm Electrophysiol (2009) 1.34

Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol (2009) 1.33

Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail (2012) 1.32

Final infarct volume is a stronger predictor of outcome than recanalization in patients with proximal middle cerebral artery occlusion treated with endovascular therapy. Stroke (2012) 1.31

Mapping epicardial fat with multi-detector computed tomography to facilitate percutaneous transepicardial arrhythmia ablation. Eur J Radiol (2006) 1.31

Catheter ablation of ventricular epicardial tissue: a comparison of standard and cooled-tip radiofrequency energy. Circulation (2004) 1.30

Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke (2015) 1.29

Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg (2012) 1.28

Variation in use of dual-chamber implantable cardioverter-defibrillators: results from the national cardiovascular data registry. Arch Intern Med (2012) 1.24

Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol (2003) 1.22

Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ (2013) 1.22

Consequences of cytotoxic T-lymphocyte escape: common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts. J Virol (2004) 1.17

Left atrial function and scar after catheter ablation of atrial fibrillation. Heart Rhythm (2008) 1.16

Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol (2005) 1.16

Six year follow-up after catheter ablation of atrial fibrillation: a palliation more than a true cure. Am J Cardiol (2012) 1.16

A cost-minimization analysis of the angio-seal vascular closure device following percutaneous coronary intervention. Am J Cardiol (2007) 1.14

Relationship between intended sites of RF ablation and post-procedural scar in AF patients, using late gadolinium enhancement cardiovascular magnetic resonance. Heart Rhythm (2009) 1.14

Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol (2006) 1.13

T-wave alternans: does size matter. J Cardiovasc Electrophysiol (2005) 1.12

Pacemaker and ICD lead extraction with electrosurgical dissection sheaths and standard transvenous extraction systems: results of a randomized trial. Europace (2007) 1.11

Mechanical approaches combined with intra-arterial pharmacological therapy are associated with higher recanalization rates than either intervention alone in revascularization of acute carotid terminus occlusion. Stroke (2009) 1.09

Differential antigen presentation kinetics of CD8+ T-cell epitopes derived from the same viral protein. J Virol (2008) 1.07

A method for the determination of proximal pulmonary vein size using contrast-enhanced magnetic resonance angiography. J Cardiovasc Magn Reson (2004) 1.06

Accelerated late gadolinium enhancement cardiac MR imaging with isotropic spatial resolution using compressed sensing: initial experience. Radiology (2012) 1.05

Effects of sex on the incidence of cardiac tamponade after catheter ablation of atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ Arrhythm Electrophysiol (2014) 1.05

Combined epicardial and endocardial electroanatomic mapping in a porcine model of healed myocardial infarction. Circulation (2003) 1.05

Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol (2008) 1.04

Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol (2004) 1.04

Mortality following defibrillator implantation in patients with renal insufficiency. J Cardiovasc Electrophysiol (2006) 1.03

Comparison of safety and clinical and radiographic outcomes in endovascular acute stroke therapy for proximal middle cerebral artery occlusion with intubation and general anesthesia versus the nonintubated state. Stroke (2010) 1.03

Effects of radiofrequency pulses delivered in the vicinity of the coronary arteries: implications for nonsurgical transthoracic epicardial catheter ablation to treat ventricular tachycardia. Pacing Clin Electrophysiol (2002) 1.02

A possible link between astrocyte activation and tau nitration in Alzheimer's disease. Neurobiol Dis (2008) 1.01

Bi-directional electrical pulmonary vein isolation as an endpoint for ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol (2007) 0.99

Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: results from the NCDR. Heart Rhythm (2014) 0.99